


**Product Name** : YJ1206  
**Cat. No.** : PC-23149  
**CAS No.** : 3053716-98-3  
**Molecular Formula** : C<sub>49</sub>H<sub>52</sub>FN<sub>11</sub>O<sub>5</sub>  
**Molecular Weight** : 894.03  
**Target** : PROTAC  
**Solubility** : 10 mM in DMSO



CAS: 3053716-98-3

### Biological Activity

YJ1206 is a selective, orally bioavailable **CDK12/13 PROTAC** degrader, shows potent degradation effects and inhibits VCaP cell viability (IC<sub>50</sub>=12.5 nM).

YJ1206 demonstrated the best PK properties, with a bioavailability over 39% by oral gavage.

YJ1206 treatment significantly increased the transcripts at the TSSs in VCaP cells, while a distinct reduction toward the TESs of the long genes ATM and ATR was observed in a time-dependent manner.

YJ1206 combined with AKT inhibitors (uprosertib, capivasertib, and MK2206) triggers a synergistic effect in vitro, The combination regimen of CDK12/13 degraders with AKT inhibitors suppresses tumor growth in vivo.

### References

Chang Y, et al. *Cell Rep Med.* 2024 Sep 21:101752. doi: 10.1016/j.xcrm.2024.101752.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com